Perazine and carbamazepine in comparison to olanzapine in schizophrenia

Neuropsychobiology

Volumn 55, Issue 2, 2007, Pages 81-88

  Ohlmeier, M D ^a,b   Jahn, K ^a   Wilhelm Gossling C ^a   Godecke Koch T ^a   Hoffmann, J ^a   Seifert, J ^a   Emrich, H M ^a   Schneider, U ^a  

^a CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Carbamazepine; Olanzapine; Perazine; Schizophrenia

Indexed keywords

CARBAMAZEPINE; OLANZAPINE; PERAZINE;

ADULT; APPETITE DISORDER; ARTICLE; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; FEMALE; HUMAN; HYPERSALIVATION; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; MUSCLE HYPOTONIA; NAUSEA; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYMPTOM; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CARBAMAZEPINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PERAZINE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 34447556949     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103906     Document Type: Article

References (40)

1. Hamilton SH, Edgell ET, Revicki DA, Breier A: Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharm 2000;15:245-255.
2. Möller H-J: Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 2000;5:329-344.
3. Kopelowicz A, Zarate R, Tripodis K, Gonzales V, Mintz J: Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157:987-993.
4. Benedetti F, Cavallaro R, Smeraldi E: Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet 1999;354:567.
5. Dettling M, Cascorbi I, Hellweg R, Deicke U, Weise L, Müller-Oerlinghausen B: Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 1999;32:110-112.
6. Naumann R, Felber W, Heilemann H, Reuster T: Olanzapine-induced agranulocytosis. Lancet 1999;354:566-567.
7. Steinwachs A, Grohmann R, Pedrosa F, Ruther E, Schwerdtner I: Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry 1999;32:154-156.
8. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
9. Donna A: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363.
10. Osser DN, Najarian DM, Dufresne RL: Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
11. Fakhoury WK, Wright D, Wallace M: Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001;16:153-162.
12. Hayek v. D, Hüttl V, Reiss J, Schweiger H-D, Füessl HS: Hyperglykämie und Ketoazidose unter Olanzapin. Nervenarzt 1999;70:836-837.
13. Lindenmayer J-P, Nathan A-M, Smith RC: Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62:30-38.
14. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S: Olanzapine for schizophrenia (Cochrane Review). Cochrane Library 2001;4:1-2.
15. Pietzcker A, Poppenberg A, Schley J, Muller-Oerlinghausen B: Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients. Arch Psychiatr Nervenkr 1981;229:315-329.
16. Grohmann R, Schmidt LG, Antretter K, Ruther E: Unwanted effects of psychotropic drugs - selected results from a 10-year multicenter project monitoring drugs in psychiatry. Internist (Berl) 1990;31:468-474.
17. Dose M, Apelt S, Emrich HM: Carbamazepine as an adjunct of antipsychotic therapy. Psychiatry Res 1987;22:303-310.
18. Klein E, Bental E, Lerer B, Belmaker RH: Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165-170.
19. Martin Munoz JC, Morinigo Dominguez AV, Mateo Martin I, Guajardo-Fajardo Ibarra I, Noval Lamos D: Carbamazepine: an efficient adjuvant treatment in schizophrenia. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1992;20:11-16.
20. Arana GW, Goff DC, Friedman H, Ornsteen M, Greenblatt DJ, Black B, Shader RI: Does carbamazepine induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry 1986;143:650-651.
21. Hesslinger B, Klose P, Normann C, Langosch JM, Berger M, Walden J: Zur adjuvanten Behandlung schizophrener Störungen mit Carbamazepin. Fortschr Neurol Psychiatr 1998;66:145-150.
22. Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J: Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999;19:310-315.
23. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N: Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216.
24. Daniel WA, Syrek M, Haduch A, Wojcikowski J: Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine. Pol J Pharmacol 1998;50:431-442.
25. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-276.
26. Overall JE, Graham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
27. Chouinard G, Ross-Chouinard A, Ananable L: Extrapyramidal Symptom Rating scale. Can J Neurol Sci 1980;7:233.
28. Benton AL: The Revised Visual Retention Test. New York, The Psychological Corporation, 1955.
29. Brickenkamp R: Aufmerksamkeits-Belastungs-Test (Test d2). Göttingen, Hogrefe, 1962.
30. Brickenkamp R, Zillmer E: The d2 Test of Attention. Seattle, Hogrefe &Huber, 1998.
31. Osswald WD, Roth E: Der Zahlen-Verbindungs-Test, 2 überarbeitete Aufl. Göttingen, Hogrefe, 1987.
32. Helmstaedter C, Durwen HF: The Verbal Learning and Retention Test. A useful and differentiated tool in evaluating verbal memory performance. Schweiz Arch Neurol Psychiatr 1990;141:21-30.
33. Lezak MD: Neuropsychological Assessment, ed 2. New York, Oxford University Press, 1983.
34. Merz J, Lehrl S, Galster V, Erzigheit H: The multiple selection vocabulary test (MSVT-B) - an accelerated intelligence test. Psychiatr Neurol Med Psychol (Leipz) 1975;27:423-428.
35. Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM: Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychiat Scand 1990;81:162-167.
36. Simhandl C und Meszaros K: The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review. J Psychiatr Neurosci 1992;17:1-14.
37. Dose M, Emrich HM: Antikonvulsiva in der Psychiatrie. Zusatzmedikation bei schizoaffektiven und schizophrenen Psychosen. Stuttgart, Verlag Kohlhammer, 2000.
38. Harvey PD, Keefe RSE: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-184.
39. Naber D: Atypische Antipsychiotika. Nervenarzt 2000;5:327-328.
40. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD: Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.